The World in a Grain of Sand: CG Oncology

The World In A Grain Of Sand

Indhold leveret af KdT Ventures. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af KdT Ventures eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

7M ago 43:43

M4A•Episode hjem

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss CG Oncology, the first biotech IPO of 2024. We dive into:

The various subtypes of bladder cancer, and one of the most unique standard of care treatment paradigms in oncology, which utilizes a live attenuated virus to treat the disease
Supply chain and manufacturing issues that have limited access to SoC therapy in bladder cancer
CG Oncology’s lead (and only) asset, an oncolytic immunotherapy which has delivered impressive complete response data in bladder cancer
Challenges and open questions around complex manufacturing, clinical and commercial adoption, and competition for CG’s lead asset
Bull vs bear case for CG Oncology

For updates from KdT, ⁠⁠subscribe to our Substack⁠⁠.

14 episoder

#Trading #Business #KdT Ventures